Found: 119
Select item for more details and to access through your institution.
Co-creation with research participants to inform the design of electronic informed consent.
- Published in:
- Digital Health, 2022, v. 8, p. 1, doi. 10.1177/20552076221109068
- By:
- Publication type:
- Article
Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1151764
- By:
- Publication type:
- Article
How to balance valuable innovation with affordable access to medicines in Belgium?
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.960701
- By:
- Publication type:
- Article
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 01, doi. 10.3389/fphar.2022.969778
- By:
- Publication type:
- Article
How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.902150
- By:
- Publication type:
- Article
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.821616
- By:
- Publication type:
- Article
Emerging Insights into European Markets of Biologics, Including Biosimilars.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 5, p. 615, doi. 10.3390/ph15050615
- By:
- Publication type:
- Article
Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 6, p. 499, doi. 10.3390/ph14060499
- By:
- Publication type:
- Article
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 3, p. 283, doi. 10.3390/ph14030283
- By:
- Publication type:
- Article
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 2, p. 117, doi. 10.3390/ph14020117
- By:
- Publication type:
- Article
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
- Published in:
- Pharmaceuticals (14248247), 2020, v. 13, n. 10, p. 324, doi. 10.3390/ph13100324
- By:
- Publication type:
- Article
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines.
- Published in:
- Applied Health Economics & Health Policy, 2022, v. 20, n. 6, p. 803, doi. 10.1007/s40258-022-00751-y
- By:
- Publication type:
- Article
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population.
- Published in:
- Applied Health Economics & Health Policy, 2019, v. 17, n. 6, p. 895, doi. 10.1007/s40258-019-00504-4
- By:
- Publication type:
- Article
Clinical, Economic and Policy Implications of Drug Shortages in the European Union.
- Published in:
- Applied Health Economics & Health Policy, 2017, v. 15, n. 4, p. 441, doi. 10.1007/s40258-016-0264-z
- By:
- Publication type:
- Article
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis.
- Published in:
- Health Research Policy & Systems, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12961-023-01015-4
- By:
- Publication type:
- Article
Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments.
- Published in:
- BMC Medical Research Methodology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12874-023-01975-9
- By:
- Publication type:
- Article
Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study.
- Published in:
- BMC Health Services Research, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12913-023-09173-5
- By:
- Publication type:
- Article
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.
- Published in:
- EMBO Reports, 2013, v. 14, n. 11, p. 951, doi. 10.1038/embor.2013.163
- By:
- Publication type:
- Article
Strengthening the global network for sharing of marine biological collections: recommendations for a new agreement for biodiversity beyond national jurisdiction.
- Published in:
- ICES Journal of Marine Science / Journal du Conseil, 2021, v. 78, n. 1, p. 305, doi. 10.1093/icesjms/fsaa227
- By:
- Publication type:
- Article
Opportunities and Challenges of Web-Based and Remotely Administered Surveys for Patient Preference Studies in a Vulnerable Population.
- Published in:
- Patient Preference & Adherence, 2021, v. 15, p. 2509, doi. 10.2147/PPA.S327006
- By:
- Publication type:
- Article
Quality and Safety Requirements for Sustainable Phage Therapy Products.
- Published in:
- Pharmaceutical Research, 2015, v. 32, n. 7, p. 2173, doi. 10.1007/s11095-014-1617-7
- By:
- Publication type:
- Article
Intellectual property policies in early-phase research in public-private partnerships.
- Published in:
- Nature Biotechnology, 2016, v. 34, n. 5, p. 504, doi. 10.1038/nbt.3562
- By:
- Publication type:
- Article
The European BRCA patent oppositions and appeals: coloring inside the lines.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 8, p. 704, doi. 10.1038/nbt.2644
- By:
- Publication type:
- Article
Legal uncertainty in the area of genetic diagnostic testing.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 10, p. 903, doi. 10.1038/nbt1009-903
- By:
- Publication type:
- Article
Using provocative design to foster electronic informed consent innovation.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Chemotherapy drug shortages in paediatric oncology: A 14-year single-centre experience in Belgium.
- Published in:
- Journal of Oncology Pharmacy Practice, 2016, v. 22, n. 6, p. 766, doi. 10.1177/1078155215610915
- By:
- Publication type:
- Article
EU-US data transfers: an enduring challenge for health research collaborations.
- Published in:
- NPJ Digital Medicine, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s41746-024-01205-6
- By:
- Publication type:
- Article
Personalized and longitudinal electronic informed consent in clinical trials: How to move the needle?
- Published in:
- Digital Health, 2024, p. 1, doi. 10.1177/20552076231222361
- By:
- Publication type:
- Article
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.
- Published in:
- Frontiers in Pharmacology, 2022, v. 12, p. 1, doi. 10.3389/fphar.2021.789640
- By:
- Publication type:
- Article
Key Determinants of Health-Related Quality of Life Among Advanced Lung Cancer Patients: A Qualitative Study in Belgium and Italy.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.710518
- By:
- Publication type:
- Article
How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.631527
- By:
- Publication type:
- Article
Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.630949
- By:
- Publication type:
- Article
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.644187
- By:
- Publication type:
- Article
What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.602112
- By:
- Publication type:
- Article
The Expiry of Humira<sup>®</sup> Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.591134
- By:
- Publication type:
- Article
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
- Published in:
- Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.594446
- By:
- Publication type:
- Article
Insights into European Drug Shortages: A Survey of Hospital Pharmacists.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0119322
- By:
- Publication type:
- Article
Call for a Dedicated European Legal Framework for Bacteriophage Therapy.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2014, v. 62, n. 2, p. 117, doi. 10.1007/s00005-014-0269-y
- By:
- Publication type:
- Article
Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2012, v. 60, n. 3, p. 161, doi. 10.1007/s00005-012-0175-0
- By:
- Publication type:
- Article
Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evolutionary trace analysis of scorpion toxins specific for K-channels (The nucleotide sequence data reported in this paper will appear in the GenBank database ( http://www.ncbi.nlm.nih.gov) under the accession numbers AY225779-AY225783 (OcKTx1-5)).
- Published in:
- Proteins, 2004, v. 54, n. 2, p. 361, doi. 10.1002/prot.10588
- By:
- Publication type:
- Article
Qualitative study on custodianship of human biological material and data stored in biobanks.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Access to human tissues for research and product development.
- Published in:
- EMBO Reports, 2015, v. 16, n. 5, p. 557, doi. 10.15252/embr.201540070
- By:
- Publication type:
- Article
The fate and future of patents on human genes and genetic diagnostic methods.
- Published in:
- Nature Reviews Genetics, 2012, v. 13, n. 6, p. 441, doi. 10.1038/nrg3255
- By:
- Publication type:
- Article
Co-creation with research participants to inform the design of electronic informed consent.
- Published in:
- Digital Health, 2022, v. 8, p. 1, doi. 10.1177/20552076221109068
- By:
- Publication type:
- Article
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.
- Published in:
- Journal of Market Access & Health Policy, 2024, v. 12, n. 1, p. 21, doi. 10.3390/jmahp12010004
- By:
- Publication type:
- Article
Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.
- Published in:
- Journal of Market Access & Health Policy, 2024, v. 12, n. 3, p. 144, doi. 10.3390/jmahp12030012
- By:
- Publication type:
- Article
The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder preconvention questionnaire.
- Published in:
- Journal of Market Access & Health Policy, 2023, v. 11, n. 1, p. 1, doi. 10.1080/20016689.2023.2217543
- By:
- Publication type:
- Article